| Name | Title | Contact Details |
|---|
Accu-Liner Products Inc is a Woodinville, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Keas is the leading Health Management platform for employers. We offer Wellbeing programs, coaching, benefits integration, and wellness incentives. Keas is dedicated to helping employers reduce health costs by reducing population health risks and encouraging smarter buying choices in healthcare. With over 70% of preventable healthcare spend wasted today, Keas leverages cutting-edge technologies in data science and behavioral economics to change behavior and slash waste, once and for all.
Deep Hospitality Knowledge Mission Hill Hospitality is the KSL Capital portfolio company launched to transform select service and extended stay hotel investing. KSL is a global leader in hospitality, travel, and leisure investing. The Mission Hill team has decades of lodging experience, with a wide range of expertise across functions including operations, asset management, acquisitions, development, and capital markets. Industry Advantage Mission Hill`s approach combines the benefits of KSL`s world-leading, world-class hospitality model, with our seasoned team`s broad relationships with owners, managers, premium brands, and developers, enabling us to create the highest quality asset portfolio. Value Added Mission Hill`s value-add strategy seeks to maximize the performance of each investment while elevating the client experience. By hand-picking assets in preferred markets across the country, we avoid inherent information asymmetry and premiums associated with acquiring a portfolio. Our disciplined approach to underwriting gives us the ability to secure outsized risk adjusted returns.
AirLife is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.